Generic drugs - The Indian scenario.
作者信息
Joshi S S, Shetty Y C, Karande S
机构信息
Department of Pharmacology and Therapeutics, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India.
Department of Pediatrics, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India.
出版信息
J Postgrad Med. 2019 Apr-Jun;65(2):67-69. doi: 10.4103/jpgm.JPGM_420_18.
Abstract
摘要
相似文献
1
Generic drugs - The Indian scenario.仿制药——印度的情况。
J Postgrad Med. 2019 Apr-Jun;65(2):67-69. doi: 10.4103/jpgm.JPGM_420_18.
2
Indian generic drugs debate heats up.印度仿制药辩论愈演愈烈。
Lancet. 2014 Oct 11;384(9951):1334. doi: 10.1016/s0140-6736(14)61803-1.
3
Prescribing generic drugs using a generic name: Are we teaching it right?使用通用名开具通用药物：我们教得对吗？
Indian J Med Ethics. 2016 Jul-Sep;1(3):194. doi: 10.20529/IJME.2016.055.
4
Indian generic drug manufacturers in the spotlight.
Lancet. 2014 Jun 28;383(9936):2186. doi: 10.1016/S0140-6736(14)61068-0.
5
Indian generic drug production. Benefits of EU-India free trade agreement.印度仿制药生产。欧盟与印度自由贸易协定的益处。
BMJ. 2011 Apr 18;342:d2439. doi: 10.1136/bmj.d2439.
6
10 years after implementation of TRIPS obligations in India.印度实施《与贸易有关的知识产权协定》（TRIPS）义务10年后。
Pharm Pat Anal. 2015;4(3):147-59. doi: 10.4155/ppa.15.12.
7
Indian Medical Association rejects call to prescribe generic drugs.印度医学协会拒绝了开具通用药物的呼吁。
BMJ. 2013 Feb 6;346:f802. doi: 10.1136/bmj.f802.
8
US drug regulator rejects accusations that it unfairly targets Indian generic firms.美国药品监管机构驳回了有关其不公平针对印度仿制药公司的指控。
BMJ. 2014 Mar 3;348:g1845. doi: 10.1136/bmj.g1845.
9
Plasma efavirenz in HIV infected children treated with generic antiretroviral drugs in India.印度接受仿制药抗逆转录病毒药物治疗的 HIV 感染儿童的血浆依非韦伦浓度。
Indian Pediatr. 2010 Oct;47(10):890-1.
10
Yusuf Hamied: leader in the Indian generic drug industry.优素福·哈米德：印度仿制药行业的领军人物。
Lancet. 2015 Dec 12;386(10011):2385. doi: 10.1016/S0140-6736(15)00839-9. Epub 2015 Nov 18.
引用本文的文献
1
Absorption, Scintigraphy, Efficacy and Tolerability of Short-Term Calcium Carbonate Supplementation in Healthy Subjects.健康受试者短期补充碳酸钙的吸收、闪烁扫描、疗效及耐受性
Cureus. 2025 Jul 9;17(7):e87642. doi: 10.7759/cureus.87642. eCollection 2025 Jul.
2
The WATCHMAN Device Is a Promising Solution for Stroke Prevention in Non-Valvular Atrial Fibrillation: Challenges and Future Directions in South and Southeast Asia.WATCHMAN装置是预防非瓣膜性心房颤动中风的一种有前景的解决方案：南亚和东南亚面临的挑战及未来方向
Cureus. 2025 May 23;17(5):e84677. doi: 10.7759/cureus.84677. eCollection 2025 May.
3
10-year diagnosis-specific antibiotic prescribing trends among paediatric inpatients at two private-sector hospitals in central India: a prospective observational study.印度中部两家私立医院儿科住院患者10年特定诊断抗生素处方趋势：一项前瞻性观察研究。
BMJ Open. 2025 Mar 13;15(3):e087901. doi: 10.1136/bmjopen-2024-087901.
4
Look-alike, sound-alike (LASA) drugs in India.印度的相似外观、相似发音（LASA）药物。
Lancet Reg Health Southeast Asia. 2024 May 16;26:100425. doi: 10.1016/j.lansea.2024.100425. eCollection 2024 Jul.
5
Pharmacoeconomic Appraisal of Treating Head and Neck Cancer with Various Chemotherapy and Chemoirradiation Regimens Using Branded and Jan-aushadhi Drugs in India.印度使用品牌药和廉价药品，采用各种化疗及放化疗方案治疗头颈癌的药物经济学评估
Indian J Otolaryngol Head Neck Surg. 2023 Sep;75(3):1782-1791. doi: 10.1007/s12070-023-03753-x. Epub 2023 Apr 8.
6
Prescription audit of a teaching hospital in South India using World Health Organization core prescribing indicators - A cross-sectional study.使用世界卫生组织核心处方指标对印度南部一家教学医院进行的处方审核——一项横断面研究。
Perspect Clin Res. 2022 Jul-Sep;13(3):132-136. doi: 10.4103/picr.PICR_172_20. Epub 2021 Jan 8.
7
Generic Anticancer Drugs of the Jan Aushadhi Scheme in India and Their Branded Counterparts: The First Cost Comparison Study.印度“平价药品计划”中的通用抗癌药物及其品牌对应药物：首次成本比较研究
Cureus. 2021 Nov 3;13(11):e19231. doi: 10.7759/cureus.19231. eCollection 2021 Nov.
8
Assessment of Patient Satisfaction with Generic Medication in Emerging Economy Using the Treatment Satisfaction Questionnaire for Medication.使用药物治疗满意度问卷评估新兴经济体中患者对仿制药的满意度
J Patient Exp. 2021 Nov 18;8:23743735211060791. doi: 10.1177/23743735211060791. eCollection 2021.
9
The use of GA-RxODE (Genetics Algorithms and Running simulations from Ordinary Differential Equations-based model) method to optimize bioequivalence studies.利用 GA-RxODE（基于遗传算法和常微分方程运行模拟的方法）优化生物等效性研究。
Pharmacol Res Perspect. 2021 Oct;9(5):e00824. doi: 10.1002/prp2.824.
10
Formulation and Cost-Effectiveness of Fluid Gels as an Age-Appropriate Dosage Form for Older Adults with Dysphagia.液质凝胶制剂作为一种适合老年吞咽障碍患者的适宜剂型的配方和成本效益
Dysphagia. 2022 Aug;37(4):1022-1034. doi: 10.1007/s00455-021-10365-6. Epub 2021 Sep 13.
本文引用的文献
1
Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending.欧美仿制药市场比较：价格、销量与支出
Milbank Q. 2017 Sep;95(3):554-601. doi: 10.1111/1468-0009.12279.
2
Prescribing generic drugs using a generic name: Are we teaching it right?使用通用名开具通用药物：我们教得对吗？
Indian J Med Ethics. 2016 Jul-Sep;1(3):194. doi: 10.20529/IJME.2016.055.
3
Bioequivalence of generic drugs: a simple explanation for a US Food and Drug Administration requirement.仿制药的生物等效性：美国食品和药物管理局要求的简单解释。
J Clin Psychiatry. 2015 Jun;76(6):e742-4. doi: 10.4088/JCP.15f10094.
4
Toward better quality of anticancer generics in India.提高印度抗癌仿制药的质量。
Indian J Cancer. 2014 July-September;51(3):366-368. doi: 10.4103/0019-509X.146723.
5
The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond.创新与竞争之间的平衡：《哈奇-沃克斯曼法案》、2003年修正案及其他相关情况
Food Drug Law J. 2011;66(3):417-78, iii.
6
A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study.对仿制药与其原创药之间的差异和相似之处进行综述，包括使用仿制药带来的经济效益，以爱尔兰为例进行研究。
BMC Pharmacol Toxicol. 2013 Jan 5;14:1. doi: 10.1186/2050-6511-14-1.
7
Policies to enhance prescribing efficiency in europe: findings and future implications.在欧洲提高处方效率的政策：发现与未来影响。
Front Pharmacol. 2011 Jan 7;1:141. doi: 10.3389/fphar.2010.00141. eCollection 2010.
Zotero 插件